SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors 24-month HOPE-3 extension data showed slower upper-limb function decline after placebo patients switched to deramiocel, drawing attention to the treatments evidence ahead of its pending FDA review. Traders largely welcomed the results as supportive of approval, while some questioned whether the open-label findings resolve the FDAs statistical and efficacy concerns.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised full-year revenue outlook, attributed to stronger demand for Amtagvi and Proleukin, is driving the sharp rally. Traders are broadly bullish, with some speculating about short covering and focusing on upcoming lung-cancer data, while others warn the move may be overextended or raise dilution concerns.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

A sharp rebound has revived breakout and accumulation talk, with bullish traders pointing to Zebecs payroll and payments adoptionespecially its Stellar enterprise rollout and SuperApp/card ecosystemas the longer-term thesis. Others question whether real usage and token demand are growing enough to support the price, noting ZBCNs history of fading gains and weak trading activity.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Positive Phase 3 results for Hetlioz in delayed sleep-wake phase disorder are driving attention, with Vanda planning to discuss the data with the FDA and seek a label expansion. Traders are optimistic about the potential new indication, while some note the small trial and that FDA approval is still pending.

Vanguard Index Funds - Vanguard Morningstar Total Stock Market ETF

Vanguard Total Stock Market ETF

Discussion centers on broad-market risk amid concerns about oil-driven inflation, elevated bond yields, government debt and stretched AI valuations; bearish traders warn of a potential correction, while others favor steadily buying and holding VTI for long-term diversification.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Upcoming PCE inflation data, elevated Treasury yields, and quarter-end positioning dominate SPY discussion, with traders debating whether rate concerns will deepen selling or softer data and easing yields will support a rebound. The conversation also reflects frustration with choppy, sharp reversals and uncertainty over the markets direction.

Armada Acquisition Corp. II is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combinations with one or more businesses. The company was founded on October 3, 2024 and is headquartered in Miami, FL.

Armada Acquisition Corp. II - Ordinary Shares- Class A

Evernorth Holdings Inc.

Evernorths SPAC merger and Nasdaq listing as XRPN, tied to its planned XRP treasury, are driving attention as traders react to approval and listing milestones alongside a sharp, volatile move. Many are bullish on XRPN and its warrants as leveraged XRP exposure, while others question the valuation and warn of merger-related and de-SPAC risk.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Discussion centers on the Trump administrations Iran conflict and uncertain diplomacy, with traders debating its effects on oil and diesel prices and broader market conditions. Political criticism and midterm speculation dominate much of the conversation, alongside a smaller bullish contingent anticipating a squeeze.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Pharvaris positive Phase 3 results for its oral hereditary angioedema prevention drug have intensified concerns that competition could pressure BioCrysts Orladeyo franchise, contributing to a sharp selloff. Traders disagree on the threats timing and scale, noting that commercialization is still years away and that BioCrysts established patient base and navenibart pipeline may help offset it.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ discussion centers on choppy trading near recent highs, with dip-buyers expecting rebounds and bears pointing to rising Treasury yields and inflation-driven rate-hike risks. Traders are watching PCE data and Micron earnings for direction, while concerns about AI spending and a possible bubble add to the debate.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
